Alumis Inc./$ALMS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Alumis Inc.
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
Ticker
$ALMS
Sector
Primary listing
Employees
223
Headquarters
Website
Alumis Inc. Metrics
BasicAdvanced
$2.9bn
-
-$2.86
-
-
Price and volume
Market cap
$2.9bn
52-week high
$30.60
52-week low
$2.76
Average daily volume
1.6m
Financial strength
Current ratio
4.34
Quick ratio
4.236
Long term debt to equity
10.702
Total debt to equity
12.252
Profitability
EBITDA (TTM)
-438.408
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-1,011.75%
Operating margin (TTM)
-1,837.44%
Effective tax rate (TTM)
3.40%
Revenue per employee (TTM)
$110,000
Management effectiveness
Return on assets (TTM)
-73.36%
Return on equity (TTM)
-86.68%
Valuation
Price to revenue (TTM)
80.929
Price to book
7.95
Price to tangible book (TTM)
9.57
Price to free cash flow (TTM)
-5.258
Free cash flow yield (TTM)
-19.02%
Free cash flow per share (TTM)
-4.353
Growth
Earnings per share change (TTM)
-72.44%
3-year earnings per share growth (CAGR)
-65.52%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Alumis Inc. stock?
Alumis Inc. (ALMS) has a market cap of $2.9B as of May 01, 2026.
What is the P/E ratio for Alumis Inc. stock?
The price to earnings (P/E) ratio for Alumis Inc. (ALMS) stock is 0 as of May 01, 2026.
Does Alumis Inc. stock pay dividends?
No, Alumis Inc. (ALMS) stock does not pay dividends to its shareholders as of May 01, 2026.
When is the next Alumis Inc. dividend payment date?
Alumis Inc. (ALMS) stock does not pay dividends to its shareholders.
What is the beta indicator for Alumis Inc.?
Alumis Inc. (ALMS) does not currently have a Beta indicator.